Canada Pension Plan Investment Board increased its position in Exact Sciences Corporation (NASDAQ:EXAS) by 1,140.2% during the second quarter, Holdings Channel reports. The firm owned 475,000 shares of the medical research company’s stock after buying an additional 436,700 shares during the period. Canada Pension Plan Investment Board’s holdings in Exact Sciences Corporation were worth $16,801,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of EXAS. Suntrust Banks Inc. raised its stake in Exact Sciences Corporation by 1.5% in the first quarter. Suntrust Banks Inc. now owns 18,478 shares of the medical research company’s stock worth $436,000 after buying an additional 277 shares during the period. Stifel Financial Corp raised its stake in Exact Sciences Corporation by 1.5% in the first quarter. Stifel Financial Corp now owns 21,475 shares of the medical research company’s stock worth $506,000 after buying an additional 310 shares during the period. Prudential Financial Inc. raised its stake in Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock worth $263,000 after buying an additional 320 shares during the period. Baker Avenue Asset Management LP raised its stake in Exact Sciences Corporation by 2.3% in the first quarter. Baker Avenue Asset Management LP now owns 35,251 shares of the medical research company’s stock worth $833,000 after buying an additional 795 shares during the period. Finally, Swiss National Bank raised its stake in Exact Sciences Corporation by 1.0% in the first quarter. Swiss National Bank now owns 179,319 shares of the medical research company’s stock worth $4,236,000 after buying an additional 1,700 shares during the period. 85.44% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Corporation (NASDAQ EXAS) opened at 38.74 on Tuesday. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $42.18. The firm’s market cap is $4.61 billion. The firm’s 50-day moving average price is $37.72 and its 200 day moving average price is $29.14.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The company had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. On average, equities research analysts forecast that Exact Sciences Corporation will post ($1.18) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/exact-sciences-corporation-nasdaqexas-shares-bought-by-canada-pension-plan-investment-board/1489313.html.

EXAS has been the topic of several recent research reports. Vetr raised shares of Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 price objective on the stock in a research report on Tuesday, July 25th. Lake Street Capital raised their price objective on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the company a “hold” rating in a research report on Wednesday, July 26th. Roth Capital raised their price objective on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cowen and Company raised their price objective on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Friday, May 5th. Finally, BTIG Research reaffirmed a “buy” rating and set a $45.00 price objective (up previously from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $40.51.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $39.41, for a total transaction of $230,390.86. Following the sale, the chief financial officer now owns 19,861 shares in the company, valued at approximately $782,722.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP D Scott Coward sold 1,987 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $35.21, for a total value of $69,962.27. Following the sale, the senior vice president now owns 57,603 shares in the company, valued at approximately $2,028,201.63. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.